8-K: Terns Pharmaceuticals Announces Upsized $150.15 Million Public Offering

Terns Pharmaceuticals has announced the pricing of an upsized public offering expected to generate approximately $150.15 million in gross proceeds.

Summary

• Terns Pharmaceuticals has priced an upsized public offering of 11,919,048 shares of common stock at $10.50 per share.
• The company is also offering pre-funded warrants to purchase 2,380,952 shares at $10.4999 per warrant.
• The gross proceeds from the offering are expected to be approximately $150.15 million, before deducting underwriting discounts and commissions.
• The underwriters have a 30-day option to purchase up to an additional 2,145,000 shares of common stock.
• The offering is expected to close on September 12, 2024, subject to customary closing conditions.
• The company intends to use the net proceeds to fund research, clinical trials, development and manufacturing of its key product candidates, including TERN-701, TERN-601, and other programs, as well as for working capital and general corporate purposes.
• The company estimates that its existing cash, cash equivalents and marketable securities, together with the estimated net proceeds from the Offering, will be sufficient to enable the Company to fund its operating expenses and capital expenditure requirements into 2028.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the successful upsized offering, which provides significant funding for the company's operations and extends its cash runway. The company's focus on oncology and obesity also aligns with current market trends.

Positives

• The upsized offering is expected to provide substantial funding for the company's research and development activities.
• The company has secured funding to extend its cash runway into 2028.
• The offering includes an underwriter option to purchase additional shares, which could further increase the capital raised.

Risks

• The company's estimates regarding the sufficiency of its cash resources are based on assumptions that may prove to be wrong.
• The company could use its available capital resources sooner than it currently expects.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to vary materially.

Future Outlook

The company anticipates using the net proceeds from the offering to fund research, clinical trials, development and manufacturing of its key product candidates, and for working capital and general corporate purposes. The company estimates that its existing cash, cash equivalents and marketable securities, together with the estimated net proceeds from the Offering, will be sufficient to enable the Company to fund its operating expenses and capital expenditure requirements into 2028.

Management Comments

• Terns intends to use the net proceeds from the proposed offering, to fund research, clinical trials, development and manufacturing of the Companys key product candidates, including TERN-701, TERN-601 and other programs, including Terns TERN-800 series, and for working capital and general corporate purposes.

Industry Context

This public offering is a common method for clinical-stage biopharmaceutical companies to raise capital to fund their research and development activities. The funds will allow Terns to continue its development programs in oncology and obesity, which are areas of significant unmet medical need and investor interest.

Comparison to Industry Standards

• The offering size and structure are typical for a clinical-stage biotech company seeking to fund its pipeline.
• Comparable companies such as Mirati Therapeutics and Arcus Biosciences have also conducted public offerings to raise capital for their drug development programs.
• The use of pre-funded warrants is a common strategy to accommodate investors who may have ownership limitations.
• The estimated cash runway into 2028 is a positive sign for investors, indicating a longer period of operational stability.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company's employees will benefit from the increased financial stability and resources for research and development.
• Customers and patients may benefit from the company's continued development of new therapies.

Next Steps

• The offering is expected to close on September 12, 2024, subject to customary closing conditions.
• The company will use the net proceeds to fund its research and development programs and for general corporate purposes.

Key Dates

Keywords

public offering, common stock, pre-funded warrants, biopharmaceutical, clinical trials, TERN-701, TERN-601, oncology, obesity, capital raise